NasdaqCM - Delayed Quote USD

Sharps Technology, Inc. (STSS)

0.2851

-0.0004

(-0.14%)

At close: April 26 at 4:00 PM EDT

Key Events

Advanced Chart

Loading Chart for STSS

9/21 12:03 PM

DELL

Previous Close 0.2855
Open 0.2850
Bid --
Ask --
Day's Range 0.2850 - 0.3000
52 Week Range 0.2700 - 1.5800
Volume 16,840
Avg. Volume 180,914
Market Cap (intraday) 4.468M
Beta (5Y Monthly) 1.03
PE Ratio (TTM) --
EPS (TTM) -0.7600
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

sharpstechnology.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Instruments & Supplies

Industry

Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems

Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia

Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

Sharps Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ: STSS)

Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private Placement

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year Purchase Agreement with Nephron Pharmaceuticals

UPDATE - Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals

Sharps Technology, Inc. CEO is Featured in an Interview with SmallCapsDaily

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

S&P 500

YTD Return

STSS

31.47%

S&P 500

6.92%

1-Year Return

STSS

69.34%

S&P 500

25.26%

3-Year Return

STSS

S&P 500

16.10%

5-Year Return

STSS

S&P 500

16.10%

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

STSS

Sharps Technology, Inc.

0.2851

-0.14%

Mkt Cap 4.468M